Skip to main content
. 2024 Nov 27;28:1–11. doi: 10.1016/j.reth.2024.11.004

Table 2.

Lipid profile parameters in normal, diabetic control and diabetic treated groups.

Parameters Normal Diabetic control Diabetic treated with glimepiride Diabetic treated with MSCs-CMT Diabetic treated with MSCs-CMP
Cholesterol (mg/dL) 102.67 ± 5.65a 211.17 ± 5.40d 178.33 ± 6.23c 144.33 ± 2.95b 105.17 ± 3.19a
Triglycerides (mg/dL) 80.83 ± 2.72a 157.60 ± 3.30d 113.67 ± 3.45c 102.67 ± 2.11b 82.00 ± 2.65a
HDL-C (mg/dL) 54.67 ± 0.88c 37.33 ± 1.09a 47.00 ± 0.63b 52.50 ± 0.99c 55.00 ± 0.45c
LDL-C (mg/dL) 32.45 ± 1.20a 134.97 ± 3.25d 113.33 ± 4.77c 70.83 ± 3.52b 36.83 ± 1.14a
vLDL-C (mg/dL) 15.55 ± 0.19a 31.70 ± 0.96d 22.67 ± 0.89c 19.33 ± 0.67b 16.32 ± 0.78a

Values are expressed as Mean ± SE of 10 rats in each group. Values, which have different superscript symbols (a, b, c and d) for each parameter, are significantly different at p < 0.05. MSCs-CMT, MSCs-CM injected daily into tail vein; MSCs-CMP, MSCs-CM injected directly in pancreas; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; vLDL-C, very low-density lipoprotein cholesterol.